Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved a wide range of recombinant DNA (r-DNA)-origin drugs and biologics for manufacture ...

Could investing in the pharmaceutical giant pay off over the next five years? I think so, and here is why. AbbVie has a ...

Prescription medication is a lifeline for millions of people around the U.S. Unfortunately, the cost of such medications has ...

As of Friday, January 23, Coherus Oncology, Inc.’s CHRS share price has surged by 21.70%, which has investors questioning if ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish strong. | UCB, AbbVie and Legend Biotech are among the companies ...

While the link between TNF inhibitor use during pregnancy/postpartum and serious infection risk was not statistically significant, an increased risk cannot be ruled out.

Shanghai Henlius Biotech, Inc. announced that it entered into an exclusive global license agreement with U-mab Biopharma ...

Johnson & Johnson ( JNJ) Q4 2025 Earnings Call January 21, 2026 8:30 AM EST Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] This ...